The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design

Nature

Volumn 443, Issue 7107, 2006, Pages 45-49

  Russell, Rupert J ^a,c   Haire, Lesley F ^a   Stevens, David J ^a   Collins, Patrick J ^a   Lin, Yi Pu ^a   Blackburn, G Michael ^b   Hay, Alan J ^a   Gamblin, Steven J ^a   Skehel, John J ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; MOLECULAR STRUCTURE; PATIENT TREATMENT; VIRUSES; X RAY CRYSTALLOGRAPHY;

ANTI-INFLUENZA MOLECULES; H5N1 AVIAN INFLUENZA NEURAMINIDASE; LIGAND BINDING;

ENZYME KINETICS;

AVIAN INFLUENZA NEURAMINIDASE; OSELTAMIVIR; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR;

BIRD; DRUG DEVELOPMENT; DRUG RESISTANCE; INFLUENZA; VIRAL DISEASE; X-RAY SPECTROSCOPY;

ARTICLE; AVIAN INFLUENZA; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TOLERANCE; ENZYME STRUCTURE; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

AVES;

EID: 33748437791     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05114     Document Type: Article

References (34)

1. Murphy, B. R. & Webster, R. G. in Fields Virology 3rd edn (eds Fields, D. B. N., Knipe, M. & Howley, P. M.) 1397-1445 (Lippincott-Raven, Philadelphia, 1996).
2. World Health Organization. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull. World Health Organ. 58, 585-591 (1980).
3. Bender, C. et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 254, 115-123 (1999).
4. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515-1521 (2005).
5. Thompson, J. D., Higgins, D. G. & Gibson, T. J. Improved sensitivity of profile searches through the use of sequence weights and gap excision. Comput. Appl. Biosci. 10, 19-29 (1994).
6. von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418-423 (1993).
7. Kim, C. U. et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119, 681-690 (1997).
8. Varghese, J. N., Laver, W. G. & Colman, P. M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 303, 35-40 (1983).
9. Baker, A. T., Varghese, J. N., Laver, W. G., Air, G. M. & Colman, P. M. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 2, 111-117 (1987).
10. Burmeister, W. P., Ruigrok, R. W. & Cusack, S. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11, 49-56 (1992).
11. Ives, J. et al. Anti-viral drug resistance: an oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo. J. Clin. Virol. 18, 251-269 (2000).
12. Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo-Hoo, Y. & Hayden, F. G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183, 523-531 (2001).
13. Carr, J. et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54, 79-88 (2002).
14. Ward, P., Small, I., Smith, J., Suter, P. & Dutkowski, R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55 (suppl. 1), i5-i21 (2005).
15. Brouillette, W. J. et al. Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents. Bioorg. Med. Chem. 11, 2739-2749 (2003).
16. Webster, R. G., Peiris, M., Chen, H. & Guan, Y. H5N1 outbreaks and enzootic influenza. Emerg. Infect. Dis. 12, 3-8 (2006).
17. Colman, P. M., Varghese, J. N. & Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303, 41-44 (1983).
18. Bossart-Whitaker, P. et al. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J. Mol. Biol. 232, 1069-1083 (1993).
19. Burmeister, W. P., Henrissat, B., Bosso, C., Cusack, S. & Ruigrok, R. W. Influenza B virus neuraminidase can synthesize its own inhibitor. Structure 1, 19-26 (1993).
20. Meindl, P., Bodo, G., Palese, P., Schulman, J. & Tuppy, H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N- acetylneuraminic acid. Virology 58, 457-463 (1974).
21. Babu, Y. S. et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43, 3482-3486 (2000).
22. Mishin, V. P., Hayden, F. G. & Gubareva, L. V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49, 4515-4520 (2005).
23. Wang, M. Z., Tai, C. Y. & Mendel, D. B. Mechanism by which mutations at His 274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46, 3809-3816 (2002).
24. Yen, H. L. et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49, 4075-4084 (2005).
25. Varghese, J. N. et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6, 735-746 (1998).
26. Le, Q. M. et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108 (2005).
27. Kiso, M. et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364, 759-765 (2004).
28. de Jong, M. D. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353, 2667-2672 (2005).
29. Crawford, P. C. et al. Transmission of equine influenza virus to dogs. Science 310, 482-485 (2005).
30. Ha, Y., Stevens, D. J., Skehel, J. J. & Wiley, D. C. X-ray structures of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs. Proc. Natl Acad. Sci. USA 98, 11181-11186 (2001).
31. Otwinowski, Z. & Minor, W. in Data Collection and Processing (eds Sawyer, L., Isaacs, N. & Bailey, S.) 556-562 (SERC Daresbury Laboratory, Warrington, 1993).
32. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D 50, 760-763 (1994).
33. Brunger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921 (1998).
34. Jones, T. A., Zhou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).